Global pharmaceutical giants are increasingly turning to Chinese biotech firms to replenish their pipelines as drugs worth $440 billion face patent expirations by 2032. Goldman Sachs analyst Salveen Richter notes that these partnerships could accelerate product development cycles for Western companies.
Licensing deals for Chinese-developed drugs have reached a total value exceeding $120 billion this year, marking a 36% increase compared to the previous year. A notable example is AstraZeneca's recent agreement to invest $2 billion in Summit Therapeutics, which licenses a cancer drug from the Chinese company Akeso.
China's latest five-year pharmaceutical plan, released on September 18, sets a goal for the country to produce at least 25% of global first-in-class drugs by 2030. The strategy also aims for 50 pharmaceutical companies to achieve annual revenues exceeding ¥10 billion, or approximately $1.5 billion, by 2030.
Despite the growth, questions remain regarding the applicability of Chinese clinical trial data to Western patient populations. The upcoming results from the Summit Therapeutics HARMONi-3 lung cancer trial, expected in the second half of 2026, are viewed as a key test for the industry's integration into Western markets.
